DECHLOROETHYLATION OF IFOSFAMIDE AND NEUROTOXICITY

The Lancet

Volumn 328, Issue 8517, 1986, Pages 1219-1220

  Goren, M P ^a   Wright, R K ^a   Pratt, C B ^a   Pell, F E ^a  

^a Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROACETALDEHYDE; CYCLOPHOSPHAMIDE; IFOSFAMIDE;

ADVERSE DRUG REACTION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; EDITORIAL; HUMAN; INTOXICATION; KIDNEY; LIVER; NERVOUS SYSTEM; NEUROTOXICITY; PHARMACOKINETICS; PRIORITY JOURNAL; THERAPY;

ACETALDEHYDE; HUMAN; IFOSFAMIDE; NERVOUS SYSTEM DISEASES;

EID: 0023035082     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(86)92227-0     Document Type: Letter

References (11)

1. Encephalopathy associated with ifosphamide/mesna therapy
2. Ifosfamide/mesna and encephalopathy
3. Avoiding ifosfamide/mesna encephalopathy
4. Prediction of ifosfamide/mesna encephalopathy
5. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma
6. Ifosfamide—pharmacology, safety and therapeutic potential
7. Central nervous system toxicity following treatment of pediatric patients with ifosfamide/mesna
8. Metabolism of cyclophosphamide by sheep
9. 2-chloroacetaldehyde, a metabolite of cyclophosphamide in the rat
10. Studies on the metabolism of isophosphamide (NSC-100974) in man
11. Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine